Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.

Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Abstract Text:

Katharina S ,Dieter Hoffmann,Hermann M ,Christian Peschel,Falko Fend,Thomas Decker,Katharina S Götze,Dieter Hoffmann,Hermann M Schätzl,Christian Peschel,Falko Fend,Thomas Decker,

We report on a patient with relapsed chronic lymphocytic leukemia (CLL) treated with the novel mTOR inhibitor RAD001 within a phase II clinical trial. Although the patient initially responded to therapy, RAD001 was discontinued after 32 weeks due to progression and fludarabine-based chemotherapy was started. The patient subsequently developed a rapidly fatal Epstein-Barr-virus-associated lymphoproliferative disorder, clonally unrelated to the CLL. The clinical course suggests caution when using newer immunosuppressive drugs for treatment of CLL, especially in the context of additional purine analog therapy.

Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Publishing Authors By Initials

KS ,D Hoffmann,HM ,C Peschel,F Fend,T Decker,KS Götze,D Hoffmann,HM Schätzl,C Peschel,F Fend,T Decker,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Haematologica

VOLUME: 92

Page Numbers: 1282-3

Journal Abbreviation: Haematologica

ISSN: 1592-8721

DAY: 4

MONTH: Sep

YEAR: 2007

Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 417435

Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.

AFFILIATION:

Country: Italy

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Haematologica

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells Related Publications

• Ability of Surface-Active Antioxidants To Inhibit Lipid Oxidation in Oil-in-Water Emulsion.
• Chronic intermitten testinal obstruction.
• Ck5-positive cells are precursor cells of glandular and myoepithelial cell lineages in the human breast epithelium. A new cell concept as a basis for a better understanding of proliferative breast disease?
• Culdoscopy; its diagnostic value in pelvic disease.
• Establishing mild, moderate, and severe scores for cancer-related symptoms: how consistent and clinically meaningful are interference-based severity cut-points?
• Evaluation of the circle of Willis with three-dimensional CT angiography in patients with suspected intracranial aneurysms.
• Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.
• Gender differences among patients with fibromyalgia undergoing multidisciplinary pain rehabilitation.
• Glyco-engineering of moss lacking plant-specific sugar residues.
• How Kraepelinian was Kraepelin? How Kraepelinian are the neo-Kraepelinians?--from Emil Kraepelin to DSM-III.
• Impact of surface-active compounds on physicochemical and oxidative properties of edible oil.
• Limits on the role of retrieval cues in memory for actions: enactment effects in the absence of object cues in the environment.
• Linked Analysis of Large Cooperative, Allosteric Systems: The Case of the Giant HBL Hemoglobins.
• Meckel's diverticulum diagnosed by double-balloon enteroscopy.
• Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition.
• Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
• Range-of-motion restriction and craniofacial tissue-interface pressure from four cervical collars.
• The Relationship of Public Health to the Doctor in Private Practice.
• The US anti-prostitution pledge: a call for cooperation.
• [Antibiotics prophylaxis in gynecologic and obstetrical surgery]
• [Determination of a series of indicans and indicanoids in urine, similar metabolic products of skatoles and 2-methyl indoles, by the fluorindal reaction, a new paper chromatographic indican reaction.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [On the vitamin A and E content of cow's milk after high doses of vitamin E.]
• [Operative management of a high abdominal aorticocaval fistula.]
• [Prolapsus uteri intra partum with native obstetrics.]
• [Treatment of cancer of the cervix uteri by endovaginal roentgenotherapy.]